TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27450411
Drug: Azithromycin maintenance
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin maintenance therapy (250/500 mg according to body weight) administered three times a week for 6 months
Study: 27450411
Drug: Azithromycin maintenance
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin maintenance therapy
Study: 20648883
Drug: Structured comprehensive
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured comprehensive oral health education (SC‐OHE)
Study: 20648883
Drug: Conventional oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional oral health education (Control Group)
Study: 18386538
Drug: Etoricoxib (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib (120 mg, tablet)
Study: 12796154
Drug: Salbutamol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (400 micro g)
Study: 12796154
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide (80 micro g)
Study: 8864639
Drug: Glimepiride (1-8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride (1-8 mg/day, once daily)
Study: 3006981
Drug: 40, 80,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40, 80, or 160 mg propranolol (non‐selective blockade)
Study: 3006981
Drug: 25, 50,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25, 50, or 100 mg atenolol (beta 1‐selective blockade)
Study: 9135343
Drug: Propofol 3
Normalized name: fospropofol 35 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 3 mg kg‐1 (group A)
Study: 9135343
Drug: Propofol 4
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol 4 mg kg‐1 (group B)
Study: 9135343
Drug: Propofol 5
Normalized name: propofol 500 MG in 50 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 5 mg kg‐1 (group C)
Study: 7971302
Drug: Standard preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard preparation (control)
Study: 29664001
Drug: Mild hypothermia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild hypothermia treatment
Study: 27484576
Drug: Intravenous glutamate
Normalized name: glutamate
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous glutamate
Study: 20386120
Drug: beta-alanine (BA,
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta-alanine (BA, n = 14) 1.5 g + 15 g dextrose powder
Study: 20386120
Drug: placebo (PL,
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (PL, n = 19) 16.5 g dextrose powder
Study: 15955378
Drug: Atypical antipsychotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atypical antipsychotics (clozapine, olanzapine, risperidone, quetiapine)
Study: 12461343
Drug: Hylan B
Normalized name: hylan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hylan B gel
Study: 10608577
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with sex steroids
Study: 1646341
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg AG-1749 (lansoprazole)
Study: 1646341
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg AG-1749 (lansoprazole)
Study: 7032303
Drug: 3% acyclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% acyclovir ointment five times daily for 14 days
Study: 7032303
Drug: 3% vidarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% vidarabine ointment five times daily for 14 days
Study: 30807853
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (81 mg daily) with tamoxifen (10 mg twice daily from 3rd to 7th day of the cycle)
Study: 30807853
Drug: Placebo (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (oral vitamin B12 tablets) with tamoxifen (10 mg twice daily from 3rd to 7th day of the cycle)
Study: 29902295
Drug: Afatinib (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afatinib (40 mg/d) with ERBB mutation-positive disease
Study: 29902295
Drug: Afatinib (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afatinib (40 mg/d) without ERBB mutation-positive disease
Study: 27081739
Drug: Standard-dose tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard-dose tacrolimus (TAC)
Study: 27081739
Drug: Everolimus plus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus plus reduced-dose tacrolimus (EVR + rTAC) in hepatitis-C sub-population
Study: 22578752
Drug: Early oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early oxytocin augmentation
Study: 22578752
Drug: Postponed oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postponed oxytocin augmentation
Study: 22578752
Drug: Both early
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both early and postponed oxytocin treatment groups
Study: 18931201
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (approximately 6 g)
Study: 10951891
Drug: nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: nedocromil sodium 2% ophthalmic solution b.i.d.
Study: 29954814
Drug: Standard-of-care chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care chemotherapy (SOC)
Study: 27254033
Drug: Bivalent oral
Normalized name: Non-US bivalent oral polio vaccine (types 1 and 3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalent oral poliovirus vaccine
Study: 25242048
Drug: Abiraterone acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Abiraterone acetate (1000 mg daily) plus prednisone (5 mg twice a day)
Study: 17687266
Drug: Lithium treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium treatment in bipolar patients
Study: 12429243
Drug: Povidone-iodine 1.25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Povidone-iodine 1.25% ophthalmic solution, one drop 4 times daily in the affected eye.
Study: 12429243
Drug: Neomycin-polymyxin-B-gramicidin ophthalmic
Normalized name: gramicidin / neomycin / polymyxin B Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neomycin-polymyxin-B-gramicidin ophthalmic solution, one drop 4 times daily in the affected eye.
Study: 12429243
Drug: Povidone-iodine 1.25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Povidone-iodine 1.25% ophthalmic solution and Neomycin-polymyxin-B-gramicidin
Study: 22492518
Drug: Dabigatran 150
Normalized name: dabigatran 150 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran 150 mg, twice daily
Study: 22492518
Drug: Dabigatran 110
Normalized name: dabigatran 110 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran 110 mg, twice daily
Study: 20424424
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment (50 microg/kg/day, n = 45)
Study: 18586683
Drug: Vitamin K-antagonist
Normalized name: Vitamin K antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K-antagonist alone
Study: 16103383
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine (0.5 mg) and sufentanil (5 microg)
Study: 16103383
Drug: Thoracic epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic epidural infusion of bupivacaine (0.25%) and fentanyl (2 microg/mL)
Study: 10443606
Drug: 125 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg/kg epsilon‐ACA followed by an infusion of 12.5 mg x kg(‐1) x h(‐1)
Study: 7821198
Drug: Segmental allergen
Normalized name: catfish allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Segmental allergen provocation with 250 PNU in 5 ml 0.9% NaCl solution of birch or grass pollen
Study: 6761088
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg clotrimazole vaginal tablets
Study: 6761088
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg econazole vaginal ovules
Study: 30006020
Drug: Second-generation electronic
Normalized name: regenerated cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-generation electronic cigarettes (ECIGs) with 0 or 18 ng/ml nicotine, used ad libitum for two weeks.
Study: 20518225
Drug: Weekly massage
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly massage treatments at work for a four week period
Study: 12557618
Drug: Co-induction group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-induction group (midazolam 3 mg, alfentanil 0.5 mg, atropine 0.5 mg, propofol)
Study: 12557618
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (alfentanil 0.5 mg, atropine 0.5 mg, propofol)
Study: 9829442
Drug: Percutaneous 17beta-estradiol
Normalized name: Estradiol-17beta
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Percutaneous 17beta-estradiol gel (1.5 mg/d)
Study: 9829442
Drug: Transdermal 17beta-estradiol
Normalized name: Estradiol-17beta
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal 17beta-estradiol patch (50 microg/d)
Study: 9829442
Drug: Oral estradiol
Normalized name: estradiol Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estradiol valerate (2 mg/d)
Study: 7911863
Drug: Metoprolol preadsorbed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol preadsorbed onto activated charcoal (100 mg metoprolol tartrate/120 mg charcoal)
Study: 7911863
Drug: Pindolol preadsorbed
Normalized name: Pindolol
DrugBank: Pindolol (DB00960)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pindolol preadsorbed onto activated charcoal (10 mg pindolol/20 mg charcoal)
Study: 7911863
Drug: Metoprolol control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol control (capsule containing the drug only)
Study: 7911863
Drug: Pindolol control
Normalized name: Pindolol
DrugBank: Pindolol (DB00960)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pindolol control (conventional tablet)
Study: 2686934
Drug: Atropine plus
Normalized name: atropine / edrophonium Injection [Enlon-Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine plus succinylcholine (2 mg/kg)
Study: 31392517
Drug: Chloroquine 500
Normalized name: chloroquine 500 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine 500 mg daily for 2-6 weeks
Study: 26227099
Drug: Corifollitropin alfa
Normalized name: corifollitropin alfa
DrugBank: Corifollitropin alfa (DB09066)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Corifollitropin alfa 150 μg (therapeutic dose)
Study: 26227099
Drug: Corifollitropin alfa
Normalized name: corifollitropin alfa
DrugBank: Corifollitropin alfa (DB09066)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Corifollitropin alfa 240 μg (supratherapeutic dose)
Study: 22403966
Drug: Gabapentin 300
Normalized name: gabapentin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 300 mg before surgery, then twice a day for 2 days
Study: 15089065
Drug: Ondansetron (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (0.15 mg/kg, n = 39)
Study: 15089065
Drug: Ondansetron plus
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ondansetron plus dexamethasone (0.15 mg/kg ondansetron and 0.2 mg/kg dexamethasone, n = 30)
Study: 10891023
Drug: Psychological questionnaires
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychological questionnaires administered at baseline to parents and participants
Study: 23949586
Drug: Vaginal suppository
Normalized name: Vaginal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal suppository (metronidazole 750 mg/miconazole nitrate 200 mg) twice a day for 7 days
Study: 23949586
Drug: Oral metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral metronidazole 2 g single dose
Study: 23949586
Drug: Vaginal suppository
Normalized name: Vaginal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal suppository (metronidazole 750 mg/miconazole nitrate 200 mg) once a day for 7 days
Study: 20075691
Drug: Cool gel
Normalized name: Menthol 2% Topical application Gel/Jelly [COOL GEL]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cool gel wrap and leg elevation intervention
Study: 17974502
Drug: Home blood
Normalized name: LifeSource Aneroid Home Blood Pressure Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home blood pressure monitoring receipt and proficiency training on its use and the Group Health secure patient website (with secure e-mail access to their healthcare provider, access to a shared medical record, prescription refill and other services)
Study: 15915035
Drug: Nefopam and
Normalized name: nefopam
DrugBank: Nefopam (DB12293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefopam and Ketoprofen combination
Study: 13130407
Drug: Tenofovir disoproxil
Normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tenofovir disoproxil fumarate (300 mg tablet once daily)
Study: 10995520
Drug: Spironolactone added
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spironolactone added to standard multidrug therapy (ACE inhibitor and loop diuretic)
Study: 10995520
Drug: Standard multidrug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard multidrug therapy (ACE inhibitor and loop diuretic)
Study: 8637535
Drug: Testosterone (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone (600 mg of testosterone enanthate weekly for 10 weeks)
Study: 1323624
Drug: Foscarnet therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foscarnet therapy (60 mg/kg every 8 h)
Study: 30545387
Drug: Crossover group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crossover group (after 3 months of exercise therapy)
Study: 30545387
Drug: BMC treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMC treatment (after crossover)
Study: 26750669
Drug: Dexmedetomidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (1 mcg/kg, iv) + midazolam (0.5 mg, iv)
Study: 26750669
Drug: Propofol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (1 mg/kg, iv) + midazolam (0.5 mg, iv)
Study: 18614450
Drug: CBT intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CBT intervention (6-month weekly group and individual sessions)
Study: 12625572
Drug: Defibrinogenation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Defibrinogenation therapy (BX group)
Study: 12625572
Drug: High-dose steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose steroid therapy (PSL group)
Study: 10587327
Drug: Rifabutin 300
Normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifabutin 300 mg and isoniazid 750 mg twice weekly for 3 months (group A)
Study: 10587327
Drug: Rifabutin 600
Normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifabutin 600 mg and isoniazid 750 mg twice weekly for 3 months (group B)
Study: 10587327
Drug: Isoniazid 300
Normalized name: isoniazid 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoniazid 300 mg/day for 6 months (group C)
Study: 8100913
Drug: Intravenous CGRP
Normalized name: CGRP
DrugBank: Calcitonin gene-related peptide (DB06379)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous CGRP (0.6 micrograms/min for 3 h per day on 5 days)
Study: 8100913
Drug: Intravenous CGRP
Normalized name: CGRP
DrugBank: Calcitonin gene-related peptide (DB06379)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous CGRP
Study: 3734845
Drug: Human lymphoblastoid
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human lymphoblastoid interferon (HLBI) 3 MU/m2, i.m. (weekly maintenance)
Study: 27653164
Drug: Zofenopril 30
Normalized name: zofenopril 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zofenopril 30 mg plus Hydrochlorothiazide 12.5 mg
Study: 27653164
Drug: Irbesartan 150
Normalized name: irbesartan 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan 150 mg plus Hydrochlorothiazide 12.5 mg
Study: 23242248
Drug: Innovator cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Innovator cisplatin formulation
Study: 23242248
Drug: Generic cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Generic cisplatin formulation
Study: 9817475
Drug: Captopril (6.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (6.25 mg test dose, followed by 12.5 mg 3 times daily for 24 hours and 25 mg 3 times daily for the next 24 hours)
Study: 9817475
Drug: Losartan (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (25 mg/day increased to 50 mg after 24 hours)
Study: 9817475
Drug: Captopril plus
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril plus Furosemide (40 mg in the morning)
Study: 8291700
Drug: Nifedipine 20
Normalized name: nifedipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 20 mg long‐acting orally 12 h before surgery and 10 mg sublingually 1.5 h before surgery
Study: 8291700
Drug: Nifedipine 10
Normalized name: nifedipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 10 mg sublingually just before induction of anesthesia
Study: 2557183
Drug: Ranitidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (150 mg orally, 10 and 2 hours before dosing)
Study: 2557183
Drug: Aluminum hydroxide
Normalized name: Aluminum Hydroxide
DrugBank: Aluminum hydroxide (DB06723)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aluminum hydroxide (120 cc)
Study: 21984584
Drug: GIP infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GIP infusion during hypoglycemia
Study: 21984584
Drug: GIP infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GIP infusion during euglycemia
Study: 21984584
Drug: GIP infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GIP infusion during hyperglycemia
Study: 21984584
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion during hypoglycemia
Study: 21984584
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion during euglycemia
Study: 21984584
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion during hyperglycemia
Study: 16501248
Drug: EHMT1-g-9441a SNP
Normalized name: ALCOHOL 350 g in 100 mL TOPICAL GEL [SNP MY FIRST HAND SANITIZER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: EHMT1-g-9441a SNP
Study: 9362356
Drug: Intra-arterial injection
Normalized name: METHOTREXATE 25 mg in 1 mL INTRA-ARTERIAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-arterial injection of 131I-labeled Lipiodol (60 mCi; 2.2 GBq) (n = 73)
Study: 9362356
Drug: Chemoembolization (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoembolization (70 mg cisplatin) (n = 69)
Study: 9362356
Drug: Intra-arterial injection
Normalized name: METHOTREXATE 25 mg in 1 mL INTRA-ARTERIAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-arterial injection of 131I-labeled Lipiodol (n = 73)
Study: 3511878
Drug: Desipramine hydrochloride
Normalized name: Desipramine Hydrochloride
DrugBank: Desipramine (DB01151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desipramine hydrochloride treatment
Study: 3511878
Drug: Desipramine therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desipramine therapy after crossover from placebo
Study: 22735175
Drug: Group cognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive behavior therapy (G-CBT) plus pharmacotherapy
Study: 22735175
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU; only pharmacotherapy)
Study: 16135476
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) for chronic insomnia
Study: 7560222
Drug: Solution A
Normalized name: I.V. SOLUTION ADDITIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution A (0.06% triclosan + 2% tween 80)
Study: 7560222
Drug: Solution B
Normalized name: DONISLECEL-JUJN RINSE SOLUTION BAG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution B (0.06% triclosan + 0.25% sodium lauryl sulphate)
Study: 31644515
Drug: Intranasal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal dexmedetomidine (DEX) 1.5 μg/kg
Study: 31644515
Drug: Intranasal saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal saline (Placebo)
Study: 23565740
Drug: Glimepiride (individually
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride (individually titrated up to 4 mg)
Study: 23565740
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (Vildagliptin and Glimepiride)
Study: 21098799
Drug: Propofol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (1 mg/kg bolus, 0.5 mg/kg top-up if needed) with fentanyl (3 μg/kg bolus)
Study: 21098799
Drug: Midazolam (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.1 mg/kg bolus, 0.1 mg/kg top-up if needed) with fentanyl (3 μg/kg bolus)
Study: 9257379
Drug: Tretinoin cream
Normalized name: Tretinoin Cream
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tretinoin cream 0.025% applied nightly
Study: 30883516
Drug: Infliximab (IFX)
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab (IFX) 5 mg/kg every 4 weeks for up to 20 weeks
Study: 29877964
Drug: ECT plus
Normalized name: Protect Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: ECT plus antipsychotic drugs (APD)
Study: 29877964
Drug: Antipsychotic drugs
Normalized name: Diazepines, oxazepines, thiazepines and oxepines antipsychotic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic drugs (APD) only
Study: 24930728
Drug: Losmapimod (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losmapimod (7.5 mg or 15.0 mg loading dose followed by 7.5 mg twice daily)